Last Price
11.01
Today's Change
-0.03 (0.27%)
Day's Change
10.81 - 11.20
Trading Volume
55,754
Market Cap
551 Million
Shares Outstanding
50 Million
Avg Volume
178,088
Avg Price (50 Days)
11.34
Avg Price (200 Days)
12.94
PE Ratio
14.30
EPS
0.77
Earnings Announcement
18-Aug-2025
Previous Close
11.04
Open
11.07
Day's Range
10.81 - 11.2
Year Range
9.755 - 17.71
Trading Volume
55,754
1 Day Change
-0.27%
5 Day Change
2.42%
1 Month Change
-5.90%
3 Month Change
-7.01%
6 Month Change
-24.07%
Ytd Change
-8.17%
1 Year Change
-24.43%
3 Year Change
-32.41%
5 Year Change
-48.29%
10 Year Change
282.29%
Max Change
259.80%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Heavenly PUNTER Lynas Boleh
Potential 20 baggers
2019-06-11 14:49